Application | Comment | Organism |
---|---|---|
drug development | drug development process aims to produce safe, effective drugs within a reasonable time and at a reasonable cost. Phase II metabolism (glucuronidation) can affect drug action and pharmacokinetics to a considerable extent. Extensive glucuronidation is an obstacle to oral bioavailability because the first-pass glucuronidation or premature clearance by UDP-glucuronosyltransferases of orally administered agents frequently results in poor oral bioavailability and lack of efficacy. Modeling of chemical entities/drugs for UGTs and their kinetic data can be useful in understanding the binding patterns to be used in the design of better molecules, analysis of first-pass glucuronidation by intestinal UGTs, including their topology, expression profile, and pharmacogenomics, and substrate selectivity at the binding pocket, structural requirements, and mechanism of enzyme actions, detailed overview | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
intestine | - |
Homo sapiens | - |
Synonyms | Comment | Organism |
---|---|---|
UDP-glucuronosyltransferase | - |
Homo sapiens |
UGT | - |
Homo sapiens |